Search results for "Double blind"

showing 10 items of 81 documents

THU0349 A Double-Blind, Randomised, Parallel Group, Active Controlled, Multicentre Study to Assess the Therapeutic Non-Inferiority of Skp-021, A 0.3%…

2014

Background NSAIDs are the first choice for management of acute musculoskeletal pain. Acute musculoskeletal pain is often associated with trauma, surgery, musculoskeletal injuries like strains, sprains and over-use injuries Objectives The primary study endpoint was the estimate of the non-inferiority of the Test drug (Ketoprofen) vs. the Reference drug (Diclofenac). This was performed by assessment of the proportion of responders (response: 50% or more reduction of baseline VAS % (95%CI) at the end of treatment) in the two treatment groups. Methods This phase III, randomised, blinded, active-control and non-inferiority study involved 697 adults with acute muskuloskeletal pain. Participants w…

Ketoprofenmedicine.medical_specialtyActivities of daily livingbusiness.industryImmunologyDiclofenac SodiumGeneral Biochemistry Genetics and Molecular BiologyDouble blindTendernessDiclofenacNon inferiorityRheumatologymedicinePhysical therapyImmunology and AllergyIn patientmedicine.symptombusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct

Anti-cytokine therapy for prevention of atherosclerosis

2015

Abstract Background Currently a chronic inflammation is considered to be the one of the most important reasons of the atherosclerosis progression. A huge amount of researches over the past few decades are devoted to study the various mechanisms of inflammation in the development of atherosclerotic lesions. Purpose To review current capabilities of anti-inflammatory therapy for the prevention and treatment of atherosclerosis and its clinical manifestations. Methods Appropriate articles on inflammatory cytokines in atherosclerosis and anti-inflammatory prevention of atherosclerosis were searched in PubMed Database from their respective inceptions until October 2015. Sections “The role of infl…

Male0301 basic medicine3003Anti-Inflammatory AgentsPharmaceutical ScienceInflammation030204 cardiovascular system & hematologyBioinformaticsProinflammatory cytokineAnti-Cytokine TherapyDouble blind03 medical and health sciences0302 clinical medicineDouble-Blind MethodDrug DiscoverymedicineAnimalsHumansInterleukin 6InflammationPharmacologybiologyTraditional medicinebusiness.industryMedicine (all)Drug Discovery3003 Pharmaceutical ScienceAtherosclerosisComplementary and Alternative Medicine2708 DermatologyHerbal preparationClinical trial030104 developmental biologyComplementary and alternative medicineAtherosclerosis preventionDisease Progressionbiology.proteinCytokinesHerbal preparationsAtherosclerosis preventionMolecular MedicinePlant Preparationsmedicine.symptomAnti-cytokine therapybusiness
researchProduct

Randomised double-blind clinical trial of intermediate- versus high-dose chloral hydrate for neuroimaging of children.

1995

Orally administered chloral hydrate is the most widely used sedative in children undergoing MRI. We compared intermediate- and high-dose oral chloral hydrate in 97 consecutive children undergoing MRI in a prospective, controlled, double-blind, randomised clinical trial. There were 50 girls and 47 boys, mean weight (+/- SD) 14.7 +/- 6.4 kg, and mean age 38 +/- 31. The children were randomly allocated to receive chloral hydrate syrup either 70 mg/kg (group A, n = 50) or 100 mg/kg (group B, n = 47). These two groups were not significantly different in sex, weight, age, diagnosis or ambulatory medication. The mean initial dose (+/- SEM) was 64 +/- 2 mg/kg for group A and 93 +/- 2 mg/kg for grou…

MaleAdolescentmedicine.drug_classSedationChloral hydrateConscious SedationGroup BDouble blindDouble-Blind MethodmedicineHumansHypnotics and SedativesRadiology Nuclear Medicine and imagingChloral HydrateProspective StudiesChildDose-Response Relationship Drugbusiness.industryInfant NewbornInfantMagnetic Resonance ImagingClinical trialEl NiñoSedativeAnesthesiaChild PreschoolAmbulatoryFemaleNeurology (clinical)medicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugNeuroradiology
researchProduct

Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomized, double blind, placebo controlled, phase III study.

2015

Objective To assess the efficacy of recombinant human erythropoietin (rhEPO) in amyotrophic lateral sclerosis (ALS). Methods Patients with probable laboratory-supported, probable or definite ALS were enrolled by 25 Italian centres and randomly assigned (1:1) to receive intravenous rhEPO 40 000 IU or placebo fortnightly as add-on treatment to riluzole 100 mg daily for 12 months. The primary composite outcome was survival, tracheotomy or >23 h non-invasive ventilation (NIV). Secondary outcomes were ALSFRS-R, slow vital capacity (sVC) and quality of life (ALSAQ-40) decline. Tolerability was evaluated analysing adverse events (AEs) causing withdrawal. The randomisation sequence was computer-…

MaleGastroenterologylaw.inventionRandomized controlled triallaw1506Amyotrophic lateral sclerosisMOTOR NEURON DISEASEeducation.field_of_studyRecombinant ProteinMiddle AgedRecombinant ProteinsTreatment OutcomePsychiatry and Mental HealthNeuromuscularSettore MED/26 - NeurologiaFemaleerythropoietyn clinical trialmedicine.drugHumanALS; MOTOR NEURON DISEASE; Adult; Aged; Amyotrophic Lateral Sclerosis; Double-Blind Method; Erythropoietin; Female; Humans; Male; Middle Aged; Recombinant Proteins; Treatment OutcomeAdultmedicine.medical_specialtyPopulationSocio-culturalePlaceboDouble blindALS; erythropoietyn clinical trialDouble-Blind MethodArts and Humanities (miscellaneous)ALS; MOTOR NEURON DISEASE; Adult; Aged; Amyotrophic Lateral Sclerosis; Double-Blind Method; Epoetin Alfa; Erythropoietin; Female; Humans; Male; Middle Aged; Recombinant Proteins; Treatment Outcome; Neurology (clinical); Psychiatry and Mental Health; Surgery; Arts and Humanities (miscellaneous)Internal medicinemedicineALS; MOTOR NEURON DISEASEHumanseducationErythropoietinAgedbusiness.industryAmyotrophic Lateral SclerosisEpoetin alfamedicine.diseaseSurgeryClinical trialEpoetin AlfaErythropoietinSurgeryNeurology (clinical)ALSbusinessAmyotrophic Lateral Sclerosi
researchProduct

An evaluation of the efficacy of a topical gel with Triester Glycerol Oxide (TGO) in the treatment of minor recurrent aphthous stomatitis in a Turkis…

2017

Background Triester glycerol oxide gel (Protefix® Queisser Pharma, Germany) is a new topical agent that has the property of adherence to the oral mucosa by forming a lipid film which protects against mechanical trauma and may help to reduce oral tissue moisture loss and inflammation. The aim of this clinical trial was to determine the efficacy of a topical TGO gel and to also compare it with triamcinolone acetonide pomade in the treatment of minor recurrent aphthous stomatitis. Material and Methods This study was a randomized, double-blind, placebo-controlled clinical trial and 180 patients with the complaint of minor aphthous ulcers were enrolled in this study. The sociodemographic data an…

MaleTriamcinolone acetonideTurkeyAdministration TopicalTABLETStriamcinolone acetonideminor recurrent aphthous stomatitisDISEASEOintmentsULCERATION0302 clinical medicineRecurrenceOral mucosaYoung adultMiddle Aged:CIENCIAS MÉDICAS [UNESCO]030205 complementary & alternative medicineTreatment Outcomemedicine.anatomical_structureULCERSCohortUNESCO::CIENCIAS MÉDICASTopical therapyFemaleStomatitis Aphthousmedicine.drugAdultmedicine.medical_specialtyAdolescentRecurrent aphthous stomatitisPlaceboDouble blindYoung Adult03 medical and health sciencesDouble-Blind MethodInternal medicinemedicinetriester glycerol oxideMANAGEMENTHumansGlucocorticoidsGeneral DentistryAgedOral Medicine and Pathologybusiness.industryResearch030206 dentistrySurgeryClinical trialOtorhinolaryngologySurgeryLASERbusinessGelsPASTE
researchProduct

Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study

2019

Background: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, characterized by progressive loss of spinal and cortical motor neurons, leading to muscular atrophy, respiratory failure, and ultimately death. There is no known cure, and the clinical benefit of the two drugs approved to treat ALS remains unclear. Novel disease-modifying therapeutics that are able to modulate the disease course are desperately needed. Our objective was to evaluate the efficacy and tolerability of Elysium Health's candidate drug EH301 in people with ALS (PALS). Methods: This was a single-center, prospective, double-blind, randomized, placebo-controlled pilot study. Thirty-two PALS we…

MaleVital CapacityPilot ProjectsGastroenterologylaw.inventionPlacebos0302 clinical medicineRandomized controlled triallawStilbenesMedicineAmyotrophic lateral sclerosisMedicamento1-(beta-D-Ribofuranosyl)nicotinamide chlorideMiddle AgedDrug CombinationsTreatment OutcomeNeurologyTolerabilityDisease ProgressionFemale35-Dimethoxy-4′-hydroxy-trans-stilbeneNiacinamidemedicine.medical_specialty3Investigación médicaPlaceboDouble blind03 medical and health sciencesAtrophyDouble-Blind MethodInternal medicinerandomized control studyHumansMuscle StrengthhumanAgedElectromyographybusiness.industryAmyotrophic Lateral Sclerosismedicine.diseaseAmyotrophic lateral sclerosis5-Dimethoxy-4 '-hydroxy-trans-stilbeneMétodo doble ciego1-(beta-D-Ribofuranosyl) nicotinamide chlorideRibonucleosidesNeurology (clinical)business030217 neurology & neurosurgeryEsclerosis amiotrófica lateral
researchProduct

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.

2013

Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and mortality of amyotrophic lateral sclerosis (ALS). Definite/probable ALS patients, 40-70 years of age, duration 6-24 months, self-sufficient (i.e. able to swallow, cut food/handle utensils, and walk), and with forced vital capacity (FVC) > 80% entered a pilot double-blind, placebo-controlled, parallel group trial and were followed for 48 weeks. ALC or placebo 3 g/day was added to riluzole 100 mg/day. Primary endpoint: number of patients no longer self-sufficient. Secondary endpoints: changes in ALSFRS-R, MRC, FVC and McGill Quality of Life (QoL) scores. Analysis was made in the intention-to-tr…

Maleamyotrophic lateral sclerosisVital CapacityPlacebo-controlled studyPilot ProjectsGastroenterologylaw.inventionRandomized controlled triallawAcetyl-L-carnitineamyotrophic lateral sclerosis; motor neuron disease; randomized trial; acetyl-l-carnitinerandomized trialAmyotrophic lateral sclerosisAcetylcarnitineALS acetyl-L-carnitineNootropic AgentsRiluzoleMiddle AgedRiluzoleTreatment OutcomeNeurologyCombinationDisease Progressionmotor neuron diseaseDrug Therapy CombinationSettore MED/26 - NeurologiaFemaleAcetylcarnitinemedicine.drugAdultmedicine.medical_specialtyAcetyl-L-carnitine amyotrophic lateral sclerosis motor neuron disease randomized trialDouble blindDouble-Blind MethodDrug TherapyInternal medicinemedicineHumansAgedMED/26 - NEUROLOGIAbusiness.industryDisease progressionmedicine.diseaseAcetyl-L-carnitineSurgeryQuality of LifeAcetylcarnitine; Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Therapy Combination; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Nootropic Agents; Pilot Projects; Quality of Life; Riluzole; Treatment Outcome; Vital CapacityNeurology (clinical)businessExcitatory Amino Acid Antagonists
researchProduct

Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease …

1984

The effect of a 3 month daily administration of 800 mg pentoxifylline (Trental 400 bds) or placebo was assessed under double blind crossover design in 18 patients (12 males and 6 females) with peripheral occlusive arterial disease in respect of painfree walking distance and various hemorheological and hemostasiological variables, platelet aggregation, serum cholesterol and triglycerides. In first treatment period walking distance significantly increased with pentoxifylline by 46% from baseline 121 ± 15 m and by 4% with placebo from baseline 134 ± 18 m. Pentoxifylline administration furthermore yielded significant decrease in whole blood and plasma viscosity and significant increase in eryt…

Malemedicine.medical_specialtyErythrocytesPlatelet Aggregationmedicine.medical_treatment030204 cardiovascular system & hematologyPlaceboPentoxifyllineDouble blindPlacebos03 medical and health sciences0302 clinical medicineDouble-Blind MethodMedicineHumansIn patient030212 general & internal medicineClinical efficacyPentoxifyllineTriglyceridesAgedChemotherapyClinical Trials as Topicbusiness.industryOcclusive arterial diseaseIntermittent ClaudicationMiddle AgedBlood ViscosityCrossover studySurgeryAdenosine DiphosphateCholesterolAnesthesiaTheobromineFemaleCollagenCardiology and Cardiovascular MedicinebusinessBlood Flow Velocitymedicine.drugAngiology
researchProduct

Turning Kurt Lewin on his head: Nothing is so theoretical as a good practice

2016

Abstract Kurt Lewin is acknowledged as the “father of social change theories” because his work has affected many models. Inspired by Lewin's massive contribution to science, this special issue of Journal of Business Research (JBR) collects papers regarding “Turning Kurt Lewin on his head: Nothing is so theoretical as a good practice.” These papers are presented in the 6th Conference of the Global Innovation and Knowledge Academy (GIKA 2016), in Valencia, Spain, from March 20 to March 23. After double blind reviews, only 75 papers are recommended to this special issue.

MarketingEntrepreneurshipPsychoanalysis05 social sciencesSocial changeCorporate innovationDouble blindNothing0502 economics and businessBusiness Research050211 marketingSociologySocial scienceGood practice050203 business & managementJournal of Business Research
researchProduct

Postoperative effects on lower third molars of using mouthwashes with super-oxidized solution versus 0.2% chlorhexidine gel : a randomized double-bli…

2018

Background The main objective of the present study is to evaluate the effects and possible benefits with regard to the postoperative period of lower third molar extractions, comparing the intraalveolar application of a bioadhesive gel of 0.2% chlorhexidine (CHX) to the use of a mouthwash with a super-oxidized solution, (SOS) Dermacyn® Wound Care (Oculus Innovative Sciences lnc., California, USA). Material and Methods A randomized double-blind study was carried out in 20 patients with a split-mouth design, with a total of 40 extractions of symmetrically impacted bilateral lower third molars. Patients were divided into two groups, a control group (C = 20) and an experimental group (D = 20). A…

MolarAdultMaleSodium HypochloriteMouthwashesDentistryMandibleTrismuslaw.inventionDouble blind030207 dermatology & venereal diseases03 medical and health sciencesWound care0302 clinical medicinePostoperative ComplicationsRandomized controlled trialDouble-Blind MethodlawMedicineEdemaHumansProspective StudiesProspective cohort studyGeneral DentistryPain PostoperativeWound HealingChlorhexidine gelbusiness.industryResearchChlorhexidineChlorhexidine030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Hypochlorous AcidDrug CombinationsOtorhinolaryngologyTooth ExtractionUNESCO::CIENCIAS MÉDICASSurgeryFemaleMolar Thirdmedicine.symptomOral SurgerybusinessGelsmedicine.drug
researchProduct